Literature DB >> 11687974

A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.

Z Hu1, I Gomes, S K Horrigan, J Kravarusic, B Mar, Z Arbieva, B Chyna, N Fulton, S Edassery, A Raza, C A Westbrook.   

Abstract

Interstitial deletion or loss of chromosome 5, del(5q) or -5, is a frequent finding in myeloid leukemias and myelodysplasias, suggesting the presence of a tumor suppressor gene within the deleted region. In our search for this gene, we identified a candidate, 5qNCA (LOC51780), which lies within a consistently-deleted segment of 5q31. 5qNCA expresses a 7.2-kb transcript with a 5286-bp open reading frame which is present at high levels in heart, skeletal muscle, kidney, placenta, and liver as well as CD34+ cells and AML cell lines. 5qNCA encodes a 191-kD nuclear protein which contains a highly-conserved C-terminus containing a zinc finger with the unique spacing Cys-X2-Cys-X7-His-X2-Cys-X2-Cys-X4-Cys-X2-Cys and a jmjC domain, which is often found in proteins that regulate chromatin remodeling. Expression of 5qNCA in a del(5q) cell line results in suppression of clonogenic growth. Preliminary sequence results in AML and MDS samples and cell lines has revealed a possible mutation in the KG-1 cell line resulting in a THR to ALA substitution that has not been found in over 100 normal alleles to date. We propose 5qNCA is a good candidate for the del(5q) tumor suppressor gene based on its predicted function and growth suppressive activities, and suggest that further mutational and functional study of this interesting gene is warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687974     DOI: 10.1038/sj.onc.1204850

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Histone demethylases and their roles in cancer epigenetics.

Authors:  Alexandra D'Oto; Qing-Wu Tian; Andrew M Davidoff; Jun Yang
Journal:  J Med Oncol Ther       Date:  2016

Review 2.  Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease.

Authors:  Paul A C Cloos; Jesper Christensen; Karl Agger; Kristian Helin
Journal:  Genes Dev       Date:  2008-05-01       Impact factor: 11.361

Review 3.  Histone demethylases and cancer.

Authors:  Sotirios C Kampranis; Philip N Tsichlis
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

4.  De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism.

Authors:  Illja J Diets; Roos van der Donk; Kristina Baltrunaite; Esmé Waanders; Margot R F Reijnders; Alexander J M Dingemans; Rolph Pfundt; Anneke T Vulto-van Silfhout; Laurens Wiel; Christian Gilissen; Julien Thevenon; Laurence Perrin; Alexandra Afenjar; Caroline Nava; Boris Keren; Sarah Bartz; Bethany Peri; Gea Beunders; Nienke Verbeek; Koen van Gassen; Isabelle Thiffault; Maxime Cadieux-Dion; Lina Huerta-Saenz; Matias Wagner; Vassiliki Konstantopoulou; Julia Vodopiutz; Matthias Griese; Annekatrien Boel; Bert Callewaert; Han G Brunner; Tjitske Kleefstra; Nicoline Hoogerbrugge; Bert B A de Vries; Vivian Hwa; Andrew Dauber; Jayne Y Hehir-Kwa; Roland P Kuiper; Marjolijn C J Jongmans
Journal:  Am J Hum Genet       Date:  2019-03-28       Impact factor: 11.025

5.  Targeting Histone Demethylases: A New Avenue for the Fight against Cancer.

Authors:  Dante Rotili; Antonello Mai
Journal:  Genes Cancer       Date:  2011-06

6.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

7.  KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.

Authors:  Ji-Young Kim; Kee-Beom Kim; Gwang Hyeon Eom; Nakwon Choe; Hae Jin Kee; Hye-Ju Son; Si-Taek Oh; Dong-Wook Kim; Jhang Ho Pak; Hee Jo Baek; Hoon Kook; Yoonsoo Hahn; Hyun Kook; Debabrata Chakravarti; Sang-Beom Seo
Journal:  Mol Cell Biol       Date:  2012-05-21       Impact factor: 4.272

8.  The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Authors:  Charlotte Pawlyn; Martin F Kaiser; Christoph Heuck; Lorenzo Melchor; Christopher P Wardell; Alex Murison; Shweta S Chavan; David C Johnson; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; David A Cairns; Eileen M Boyle; John R Jones; Gordon Cook; Mark T Drayson; Roger G Owen; Walter M Gregory; Graham H Jackson; Bart Barlogie; Faith E Davies; Brian A Walker; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2016-05-27       Impact factor: 12.531

9.  Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.

Authors:  Margaret E McLaughlin-Drubin; Donglim Park; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-17       Impact factor: 11.205

10.  Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.

Authors:  Timothy A Graubert; Michelle A Payton; Jin Shao; Richard A Walgren; Ryan S Monahan; John L Frater; Mark A Walshauser; Mike G Martin; Yumi Kasai; Matthew J Walter
Journal:  PLoS One       Date:  2009-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.